Regeneron, Ocular Ink Deal for New Eylea Formulation

Oct. 14, 2016

Ocular Therapeutix and Regeneron Pharmaceuticals have announced a $315 million deal to develop a sustained-release form of Regeneron’s Eylea.

Eylea generated $3.24 billion in sales in 2015 and now Regeneron is looking to develop a formulation that will cut down on injection frequency in patients suffering from wet age-related macular degeneration.

Under the terms of the deal, Bedford, MA-based Ocular is responsible for the costs of developing the formulation through Phase 1, and Regeneron will take over development, FDA filing, and commercialization, if it’s approved.

Read the press release